Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D'Incalci

Showing results (81-90 of 339) with videos related to

Pageof 34
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testisM Arboix, O G Paz, T Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1991
AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer ResearchM D'Incalci, H J Broxterman, C K van Kalken
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1993
Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolismM Zucchetti, M Zambetti, J M Hartley, et al.
Gynecologic Oncology|December 1, 1981
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapyC Mangioni, S Franceschi, C La Vecchia, et al.
Journal of Chromatography. B, Biomedical Applications|July 1, 1994
Determination of L-asparagine in biological samples in the presence of L-asparaginaseD Gentili, M Zucchetti, V Conter, et al.
British Journal of Cancer|March 1, 1988
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenograftsR Giavazzi, A Garofalo, G Damia, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patientsM Zucchetti, M D'Incalci, Y Willems, et al.
Cancer Treatment Reports|January 1, 1985
Pharmacokinetics of etoposide in gestochoriocarcinomaM D'Incalci, C Sessa, C Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cellsE Erba, S Ronzoni, L Bassano, et al.
Cancer Treatment Reports|January 1, 1981
Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapyC Sessa, G Bolis, I Valente, et al.
Pageof 34

Showing results (81-90 of 339) with videos related to

Sort By:
Pageof 34
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testisM Arboix, O G Paz, T Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1991
AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer ResearchM D'Incalci, H J Broxterman, C K van Kalken
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1993
Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolismM Zucchetti, M Zambetti, J M Hartley, et al.
Gynecologic Oncology|December 1, 1981
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapyC Mangioni, S Franceschi, C La Vecchia, et al.
Journal of Chromatography. B, Biomedical Applications|July 1, 1994
Determination of L-asparagine in biological samples in the presence of L-asparaginaseD Gentili, M Zucchetti, V Conter, et al.
British Journal of Cancer|March 1, 1988
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenograftsR Giavazzi, A Garofalo, G Damia, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patientsM Zucchetti, M D'Incalci, Y Willems, et al.
Cancer Treatment Reports|January 1, 1985
Pharmacokinetics of etoposide in gestochoriocarcinomaM D'Incalci, C Sessa, C Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cellsE Erba, S Ronzoni, L Bassano, et al.
Cancer Treatment Reports|January 1, 1981
Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapyC Sessa, G Bolis, I Valente, et al.
Pageof 34